首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2102976

全球嗜睡症治療市場：策略性洞察與預測（2026-2035 年）

Global Narcolepsy Treatment Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

根據《全球嗜睡症治療市場趨勢報告》，預計市場規模將從 2026 年的 15.6 億美元成長到 2035 年的 31 億美元，複合年成長率為 7.9%。

發作性睡病是一種慢性神經系統睡眠障礙，其特徵為白天過度嗜睡、猝倒、睡眠癱瘓、入睡幻覺和夜間睡眠障礙。目前的治療主要集中於症狀管理，包括使用促醒劑、羥考酮鈉療法、興奮劑和抗憂鬱症。隨著Orexin受體促效劑和其他旨在解決該疾病潛在病理生理機制的疾病修正治療的研發，治療格局正在迅速變化。

市場促進因素

發作性睡病診斷數量增加

醫療專業人員意識的提高、診斷技術的進步以及專業睡眠中心的擴張，導致全球睡眠障礙患者數量不斷增加。早期診斷有助於及時啟動治療，從而促進市場成長。

新治療方法的進展

Orexin受體促效劑的出現、羥丁酸鈉製劑的改良以及新一代興奮劑的問世，大大拓展了治療選擇。這些療法旨在更好地控制症狀、提高患者的遵守用藥並改善生活品質。

擴大對醫療領域的投資

醫療保健系統正增加對睡眠醫學基礎設施、神經系統疾病治療和罕見疾病管理的投入。政府的支持和優惠的孤兒藥政策持續推動嗜睡症治療領域製藥業的創新。

提高患者意識

睡眠醫學組織和患者支持團體所進行的宣傳活動正在促進早期診斷和提高治療依從率，從而進一步提高對有效治療的需求。

市場限制因素

漏診和延誤診斷

由於發作性睡病的症狀常常與其他神經系統疾病、精神疾病或睡眠障礙重疊，因此在許多國家仍嚴重漏診。這種診斷延誤持續阻礙及時治療。

先進療法的高成本

創新療法，特別是最近核准的製劑和新興生物製藥，可能會對報銷範圍有限的醫療保健系統造成成本挑戰。

專業人才短缺

在開發中地區，睡眠專家和先進診斷設施的普及程度仍然不均衡，限制了人們獲得治療的機會。

對治療和技術的見解

全球嗜睡症治療市場可按藥物分類、疾病類型、年齡層、通路、最終用戶和地區進行細分。

按藥物分類，市場包括興奮劑、羥丁酸鈉療法、興奮劑、抗憂鬱症、Orexin受體促效劑和其他輔助療法。由於興奮劑和羥丁酸鈉療法已被證實能有效控制白天過度嗜睡和猝倒，因此目前它們在治療中佔據相當大的佔有率。隨著Orexin受體促效劑的商業化程度不斷提高，預計它們將成為成長最快的治療類別之一。

依疾病類型分類，市場由 1 型嗜睡症和 2 型嗜睡症組成。 1 型嗜睡症佔據了更大的治療市場佔有率，因為患者通常同時出現白天過度嗜睡和猝倒，需要全面的治療管理。

從年齡層來看，治療對象包括兒童、青少年、成人和老年人。目前，成人患者是最大的治療群體，但隨著診斷技術的進步，預計兒童治療範圍也將擴大。

就通路而言，治療藥物透過醫院藥房、普通藥房、專科藥房和線上藥房供應。專科藥局在管理高階治療和支持患者長期用藥依從性方面的重要性日益凸顯。

包括數位睡眠監測、遠端醫療、穿戴式睡眠評估設備、人工智慧 (AI) 驅動的診斷和精準醫療在內的技術創新，正在改善疾病管理和患者的長期療效。

市場趨勢

嗜睡症的治療格局正在快速改變。

主要趨勢如下：

Orexin受體促效劑療法的推廣。
擴大緩釋羥考酮鈉製劑的應用。
擴大精準醫療在睡眠障礙領域的應用。
進一步整合數位醫療技術。
加大對罕見神經系統疾病的投入。
擴大遠端醫療在病患監測的應用。
人們對疾病修正治療的興趣日益濃厚。

區域趨勢

由於北美擁有先進的睡眠醫學基礎設施、強大的藥物創新能力、有利的保險報銷政策以及廣泛的專業護理服務，因此北美仍然是嗜睡症治療的最大市場。

歐洲憑藉其完善的醫療保健體系、成熟的睡眠醫學網路以及創新療法的不斷普及，保持著相當大的市場佔有率。

由於中國、日本、印度、韓國和澳洲等國醫療基礎設施的改善、診斷率的提高、醫療支出的增加以及人們健康意識的增強，亞太地區預計將成為成長最快的地區。

在拉丁美洲、中東和非洲，隨著醫療保健投資的增加、專家的培訓以及對睡眠障礙的意識提高，獲得治療的機會不斷改善。

競爭格局

全球嗜睡症治療市場包括跨國製藥公司、生技公司、神經科專家和睡眠醫學研發公司。

各公司持續投資於Orexin受體促效劑、改良的羥考酮鈉製劑、喚醒增強療法、精準神經學和數位健康技術。策略聯盟、授權協議、收購和臨床夥伴關係仍然是加速療法創新和商業化的關鍵。領先公司包括 Jazz Pharmaceuticals plc、Harmony Biosciences Holdings Inc.、武田藥品工業株式會社、Avadel Pharmaceuticals plc、Axsome Therapeutics Inc.、Alkermes plc 和 Centessa Pharmaceuticals plc。

未來展望

嗜睡症治療市場的未來將受到Orexin生物學、個人化醫療、數位健康以及疾病修正治療不斷進步的融合影響。隨著新一代Orexin標靶治療逐步走向商業化，市場預計將從症狀治療轉向更直接針對嗜睡症潛在機制的療法。

預計到 2035 年，加大研發投入、改善監管流程以及提高病患意識將為創新創造重大機會。

結論

預計到2035年，全球嗜睡症治療市場將持續成長，這主要得益於診斷率的提高、治療技術的創新以及對睡眠神經科學的深入了解。儘管診斷延遲、保險報銷難題以及專科醫生資源有限仍然是重要的障礙，Orexin標靶療法、數位健康技術和精準醫療的持續進步有望改善患者的治療效果，同時為製藥公司、生物技術公司、醫療服務提供者和投資者創造極具吸引力的機會。

本報告的主要益處

對全球嗜睡症治療市場及未來成長機會進行全面分析。
對治療方法、治療創新和技術趨勢進行詳細評估。
對主要企業的競爭力評估、策略措施和產品開發進行分析。
深入了解監理趨勢、保險報銷趨勢和商業化機會。
這將成為製藥公司、生技公司、醫療保健提供者、投資者、顧問和政策制定者的重要資訊來源。

公司對我們報告的使用

治療環境評估、市場預測、競爭情報分析、產品系列開發、商業化策略、許可和合作評估、投資分析、市場進入計劃和長期策略決策。

調查範圍

歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
對全球嗜睡症治療市場進行全面分析，分析維度包括藥物分類、疾病類型、年齡層、分銷管道、最終用戶和地區。
評估市場規模、治療普及、競爭格局、法規環境、技術趨勢和未來成長機會。
策略聯盟、臨床創新、併購、商業化策略和保險報銷評估。
對興奮劑、羥考酮鈉療法、興奮劑、抗憂鬱症、Orexin受體促效劑、數位健康解決方案、精準醫療以及 2035 年的未來治療機會進行分析。

Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep. Current treatment primarily focuses on symptom management using wake-promoting agents, sodium oxybate therapies, stimulants, and antidepressants. The treatment landscape is rapidly evolving with the development of orexin receptor agonists and other disease-modifying therapies designed to address the underlying pathophysiology of the disease.

Market Drivers

Increasing Diagnosis of Narcolepsy

Growing awareness among healthcare professionals, improved diagnostic techniques, and expansion of specialized sleep centers are increasing the number of diagnosed patients worldwide. Earlier diagnosis enables timely treatment initiation and supports market growth.

Advancements in Novel Therapies

The emergence of orexin receptor agonists, improved sodium oxybate formulations, and next-generation wake-promoting agents is significantly expanding treatment options. These therapies aim to provide better symptom control, improved patient adherence, and enhanced quality of life.

Rising Healthcare Investment

Healthcare systems are investing more heavily in sleep medicine infrastructure, neurological care, and rare disease management. Government support and favorable orphan drug policies continue encouraging pharmaceutical innovation in narcolepsy treatment.

Growing Patient Awareness

Educational initiatives by sleep medicine organizations and patient advocacy groups are encouraging earlier diagnosis and increasing treatment adherence, further supporting demand for effective therapies.

Market Restraints

Underdiagnosis and Diagnostic Delays

Narcolepsy remains significantly underdiagnosed in many countries because symptoms often overlap with other neurological, psychiatric, or sleep disorders. Long diagnostic delays continue to limit timely treatment.

High Cost of Advanced Therapies

Innovative therapies, particularly recently approved formulations and emerging biologics, may present affordability challenges in healthcare systems with limited reimbursement coverage.

Limited Specialist Availability

Access to sleep specialists and advanced diagnostic facilities remains uneven across developing regions, restricting treatment availability.

Treatment and Technology Insights

The global narcolepsy treatment market can be segmented by drug class, disease type, age group, distribution channel, end user, and geography.

By drug class, the market includes wake-promoting agents, sodium oxybate therapies, stimulants, antidepressants, orexin receptor agonists, and other supportive therapies. Wake-promoting agents and sodium oxybate therapies currently account for a substantial share of treatment because of their proven effectiveness in managing excessive daytime sleepiness and cataplexy. Orexin receptor agonists are expected to become one of the fastest-growing therapeutic classes as they move toward broader commercialization.

By disease type, the market comprises Narcolepsy Type 1 and Narcolepsy Type 2. Narcolepsy Type 1 represents the larger treatment segment because patients often experience both excessive daytime sleepiness and cataplexy, requiring comprehensive therapeutic management.

By age group, treatment includes pediatric patients, adolescents, adults, and elderly patients. Adults account for the largest treatment population, while pediatric treatment is expected to expand as diagnosis improves.

By distribution channel, therapies are supplied through hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. Specialty pharmacies continue to gain importance for managing advanced therapies and supporting long-term patient adherence.

Technological innovation continues through digital sleep monitoring, telemedicine, wearable sleep assessment devices, artificial intelligence-assisted diagnostics, and precision medicine, improving disease management and long-term patient outcomes.

Market Trends

The narcolepsy treatment landscape continues to evolve rapidly.

Key trends include:

Expansion of orexin receptor agonist therapies.
Increasing adoption of extended-release sodium oxybate formulations.
Growing use of precision medicine in sleep disorders.
Greater integration of digital health technologies.
Increasing investment in rare neurological diseases.
Expansion of telemedicine for long-term patient monitoring.
Growing focus on disease-modifying therapeutic approaches.

Regional Insights

North America remains the largest narcolepsy treatment market because of advanced sleep medicine infrastructure, strong pharmaceutical innovation, favorable reimbursement policies, and widespread availability of specialist care.

Europe maintains a significant market share through comprehensive healthcare systems, established sleep medicine networks, and increasing adoption of innovative therapies.

Asia-Pacific is expected to register the fastest growth owing to improving healthcare infrastructure, expanding diagnosis rates, increasing healthcare expenditure, and growing awareness across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa continue to improve treatment access through expanding healthcare investment, specialist training, and greater awareness of sleep disorders.

Competitive Landscape

The global narcolepsy treatment market includes multinational pharmaceutical companies, biotechnology firms, specialty neurology companies, and sleep medicine developers.

Organizations continue investing in orexin receptor agonists, improved sodium oxybate formulations, wake-promoting therapies, precision neurology, and digital health technologies. Strategic collaborations, licensing agreements, acquisitions, and clinical partnerships remain central to accelerating therapeutic innovation and commercialization. Major companies include Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc., Takeda Pharmaceutical Company Limited, Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Alkermes plc, and Centessa Pharmaceuticals plc.

Future Outlook

The future of the narcolepsy treatment market will be shaped by continued advances in orexin biology, personalized medicine, digital health integration, and disease-modifying therapies. As next-generation orexin-targeted treatments progress toward commercialization, the market is expected to transition from symptomatic management toward therapies that more directly address the underlying mechanisms of narcolepsy.

Growing research investment, supportive regulatory pathways, and expanding patient awareness are expected to create substantial opportunities for innovation through 2035.

Conclusion

The Global Narcolepsy Treatment Market is expected to demonstrate sustained growth through 2035, supported by increasing diagnosis rates, expanding therapeutic innovation, and improved understanding of sleep neuroscience. Although diagnostic delays, reimbursement challenges, and limited specialist access remain important barriers, continued advances in orexin-targeted therapies, digital health technologies, and precision medicine are expected to improve patient outcomes while creating attractive opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

Comprehensive analysis of the global narcolepsy treatment market and future growth opportunities.
Detailed evaluation of treatment modalities, therapeutic innovations, and technology trends.
Competitive assessment of leading companies, strategic initiatives, and product development.
Insights into regulatory developments, reimbursement trends, and commercialization opportunities.
Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Treatment landscape assessment, market forecasting, competitive intelligence, product portfolio planning, commercialization strategy, licensing and partnership evaluation, investment analysis, market access planning, and long-term strategic decision-making.

Report Coverage

Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
Comprehensive analysis of the global narcolepsy treatment market by drug class, disease type, age group, distribution channel, end user, and geography
Evaluation of market size, treatment adoption, competitive dynamics, regulatory environment, technology trends, and future growth opportunities
Assessment of strategic collaborations, clinical innovation, mergers and acquisitions, commercialization strategies, and reimbursement landscape
Analysis of wake-promoting agents, sodium oxybate therapies, stimulants, antidepressants, orexin receptor agonists, digital health solutions, precision medicine, and future treatment opportunities through 2035.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Treatment Landscape Highlights
1.4 Current Standard of Care Overview
1.5 Emerging Treatment Trends
1.6 Unmet Needs Assessment
1.7 Strategic Insights
1.8 Future Outlook

2. Disease Overview

2.1 Introduction to Narcolepsy
2.2 Disease Classification
- 2.2.1 Narcolepsy Type 1
- 2.2.2 Narcolepsy Type 2
- 2.2.3 Secondary Narcolepsy
2.3 Disease Pathophysiology
2.4 Orexin/Hypocretin Deficiency Mechanism
2.5 Epidemiology Overview
2.6 Clinical Manifestations
- 2.6.1 Excessive Daytime Sleepiness
- 2.6.2 Cataplexy
- 2.6.3 Sleep Paralysis
- 2.6.4 Hypnagogic Hallucinations
- 2.6.5 Fragmented Nighttime Sleep
2.7 Disease Burden Assessment
2.8 Unmet Medical Needs

3. Treatment Landscape Overview

3.1 Evolution of Narcolepsy Treatment
3.2 Historical Treatment Milestones
3.3 Current Treatment Paradigm
3.4 Treatment Algorithm Analysis
3.5 Patient Journey and Treatment Flow
3.6 Treatment Challenges
3.7 Future Treatment Direction

4. Pharmacological Treatment Landscape

4.1 Wake-Promoting Agents
- 4.1.1 Treatment Overview
- 4.1.2 Clinical Benefits
- 4.1.3 Safety Profile
- 4.1.4 Prescribing Trends
- 4.1.5 Future Outlook
4.2 Sodium Oxybate Therapies
- 4.2.1 Treatment Overview
- 4.2.2 Clinical Benefits
- 4.2.3 Safety Profile
- 4.2.4 Prescribing Trends
- 4.2.5 Future Outlook
4.3 Low-Sodium Oxybate Therapies
- 4.3.1 Treatment Overview
- 4.3.2 Clinical Benefits
- 4.3.3 Safety Profile
- 4.3.4 Prescribing Trends
- 4.3.5 Future Outlook
4.4 Histamine H3 Receptor Antagonists/Inverse Agonists
- 4.4.1 Treatment Overview
- 4.4.2 Clinical Benefits
- 4.4.3 Safety Profile
- 4.4.4 Prescribing Trends
- 4.4.5 Future Outlook
4.5 Central Nervous System Stimulants
- 4.5.1 Treatment Overview
- 4.5.2 Clinical Benefits
- 4.5.3 Safety Profile
- 4.5.4 Prescribing Trends
- 4.5.5 Future Outlook
4.6 Antidepressants for Cataplexy Management
- 4.6.1 Treatment Overview
- 4.6.2 Clinical Benefits
- 4.6.3 Safety Profile
- 4.6.4 Prescribing Trends
- 4.6.5 Future Outlook

5. Non-Pharmacological Treatment Landscape

5.1 Lifestyle Management Approaches
- 5.1.1 Scheduled Naps
- 5.1.2 Sleep Hygiene Interventions
- 5.1.3 Behavioral Modifications
- 5.1.4 Future Outlook
5.2 Cognitive and Behavioral Interventions
- 5.2.1 Cognitive Behavioral Therapy
- 5.2.2 Patient Education Programs
- 5.2.3 Supportive Care Strategies
- 5.2.4 Future Outlook
5.3 Multidisciplinary Care Models
- 5.3.1 Sleep Specialist Management
- 5.3.2 Neurology-Based Care
- 5.3.3 Integrated Care Approaches
- 5.3.4 Future Outlook

6. Treatment Landscape by Disease Type

6.1 Narcolepsy Type 1
- 6.1.1 Current Treatment Practices
- 6.1.2 Treatment Utilization Trends
- 6.1.3 Future Outlook
6.2 Narcolepsy Type 2
- 6.2.1 Current Treatment Practices
- 6.2.2 Treatment Utilization Trends
- 6.2.3 Future Outlook
6.3 Pediatric Narcolepsy
- 6.3.1 Current Treatment Practices
- 6.3.2 Treatment Utilization Trends
- 6.3.3 Future Outlook
6.4 Adult Narcolepsy
- 6.4.1 Current Treatment Practices
- 6.4.2 Treatment Utilization Trends
- 6.4.3 Future Outlook

7. Treatment Landscape by Symptom Management

7.1 Excessive Daytime Sleepiness
- 7.1.1 Current Treatment Options
- 7.1.2 Treatment Adoption Trends
- 7.1.3 Future Outlook
7.2 Cataplexy
- 7.2.1 Current Treatment Options
- 7.2.2 Treatment Adoption Trends
- 7.2.3 Future Outlook
7.3 Sleep Paralysis
- 7.3.1 Current Treatment Options
- 7.3.2 Treatment Adoption Trends
- 7.3.3 Future Outlook
7.4 Hallucinations
- 7.4.1 Current Treatment Options
- 7.4.2 Treatment Adoption Trends
- 7.4.3 Future Outlook
7.5 Nighttime Sleep Disturbances
- 7.5.1 Current Treatment Options
- 7.5.2 Treatment Adoption Trends
- 7.5.3 Future Outlook

8. Emerging Treatment Landscape

8.1 Orexin Receptor Agonists
- 8.1.1 Clinical Development Status
- 8.1.2 Mechanism of Action
- 8.1.3 Competitive Assessment
- 8.1.4 Future Outlook
8.2 Novel Wake-Promoting Agents
- 8.2.1 Clinical Development Status
- 8.2.2 Mechanism of Action
- 8.2.3 Competitive Assessment
- 8.2.4 Future Outlook
8.3 Immunomodulatory Therapies
- 8.3.1 Clinical Development Status
- 8.3.2 Mechanism of Action
- 8.3.3 Competitive Assessment
- 8.3.4 Future Outlook
8.4 Gene and Cell-Based Therapies
- 8.4.1 Clinical Development Status
- 8.4.2 Mechanism of Action
- 8.4.3 Competitive Assessment
- 8.4.4 Future Outlook

9. Treatment Guidelines and Clinical Practice

9.1 International Treatment Guidelines
9.2 American Academy of Sleep Medicine Recommendations
9.3 European Treatment Recommendations
9.4 Japanese Treatment Recommendations
9.5 Treatment Sequencing Strategies
9.6 Physician Prescribing Patterns
9.7 Future Guideline Evolution

10. Geographical Analysis

10.1 North America
- 10.1.1 Treatment Utilization Trends
- 10.1.2 Standard of Care Assessment
- 10.1.3 Access to Treatment
- 10.1.4 Reimbursement Environment
- 10.1.5 Key Market Drivers
- 10.1.6 Growth Opportunities
10.2 Europe
- 10.2.1 Treatment Utilization Trends
- 10.2.2 Standard of Care Assessment
- 10.2.3 Access to Treatment
- 10.2.4 Reimbursement Environment
- 10.2.5 Key Market Drivers
- 10.2.6 Growth Opportunities
10.3 Asia-Pacific
- 10.3.1 Treatment Utilization Trends
- 10.3.2 Standard of Care Assessment
- 10.3.3 Access to Treatment
- 10.3.4 Reimbursement Environment
- 10.3.5 Key Market Drivers
- 10.3.6 Growth Opportunities
10.4 Latin America
- 10.4.1 Treatment Utilization Trends
- 10.4.2 Standard of Care Assessment
- 10.4.3 Access to Treatment
- 10.4.4 Reimbursement Environment
- 10.4.5 Key Market Drivers
- 10.4.6 Growth Opportunities
10.5 Middle East & Africa
- 10.5.1 Treatment Utilization Trends
- 10.5.2 Standard of Care Assessment
- 10.5.3 Access to Treatment
- 10.5.4 Reimbursement Environment
- 10.5.5 Key Market Drivers
- 10.5.6 Growth Opportunities

11. Key Countries Analysis

11.1 United States
- 11.1.1 Treatment Utilization Trends
- 11.1.2 Prescribing Patterns
- 11.1.3 Access to Treatment
- 11.1.4 Reimbursement Environment
- 11.1.5 Key Market Drivers
- 11.1.6 Growth Opportunities
11.2 Canada
- 11.2.1 Treatment Utilization Trends
- 11.2.2 Prescribing Patterns
- 11.2.3 Access to Treatment
- 11.2.4 Reimbursement Environment
- 11.2.5 Key Market Drivers
- 11.2.6 Growth Opportunities
11.3 Germany
- 11.3.1 Treatment Utilization Trends
- 11.3.2 Prescribing Patterns
- 11.3.3 Access to Treatment
- 11.3.4 Reimbursement Environment
- 11.3.5 Key Market Drivers
- 11.3.6 Growth Opportunities
11.4 United Kingdom
- 11.4.1 Treatment Utilization Trends
- 11.4.2 Prescribing Patterns
- 11.4.3 Access to Treatment
- 11.4.4 Reimbursement Environment
- 11.4.5 Key Market Drivers
- 11.4.6 Growth Opportunities
11.5 France
- 11.5.1 Treatment Utilization Trends
- 11.5.2 Prescribing Patterns
- 11.5.3 Access to Treatment
- 11.5.4 Reimbursement Environment
- 11.5.5 Key Market Drivers
- 11.5.6 Growth Opportunities
11.6 Italy
- 11.6.1 Treatment Utilization Trends
- 11.6.2 Prescribing Patterns
- 11.6.3 Access to Treatment
- 11.6.4 Reimbursement Environment
- 11.6.5 Key Market Drivers
- 11.6.6 Growth Opportunities
11.7 Spain
- 11.7.1 Treatment Utilization Trends
- 11.7.2 Prescribing Patterns
- 11.7.3 Access to Treatment
- 11.7.4 Reimbursement Environment
- 11.7.5 Key Market Drivers
- 11.7.6 Growth Opportunities
11.8 China
- 11.8.1 Treatment Utilization Trends
- 11.8.2 Prescribing Patterns
- 11.8.3 Access to Treatment
- 11.8.4 Reimbursement Environment
- 11.8.5 Key Market Drivers
- 11.8.6 Growth Opportunities
11.9 Japan
- 11.9.1 Treatment Utilization Trends
- 11.9.2 Prescribing Patterns
- 11.9.3 Access to Treatment
- 11.9.4 Reimbursement Environment
- 11.9.5 Key Market Drivers
- 11.9.6 Growth Opportunities
11.10 India
- 11.10.1 Treatment Utilization Trends
- 11.10.2 Prescribing Patterns
- 11.10.3 Access to Treatment
- 11.10.4 Reimbursement Environment
- 11.10.5 Key Market Drivers
- 11.10.6 Growth Opportunities
11.11 South Korea
- 11.11.1 Treatment Utilization Trends
- 11.11.2 Prescribing Patterns
- 11.11.3 Access to Treatment
- 11.11.4 Reimbursement Environment
- 11.11.5 Key Market Drivers
- 11.11.6 Growth Opportunities
11.12 Australia
- 11.12.1 Treatment Utilization Trends
- 11.12.2 Prescribing Patterns
- 11.12.3 Access to Treatment
- 11.12.4 Reimbursement Environment
- 11.12.5 Key Market Drivers
- 11.12.6 Growth Opportunities

12. Company Profiles

12.1 Jazz Pharmaceuticals plc
- 12.1.1 Overview
- 12.1.2 Financials
- 12.1.3 Narcolepsy Treatment Portfolio
- 12.1.4 Commercial Strategy
- 12.1.5 Key Products
- 12.1.6 Market Position
- 12.1.7 Strategic Collaborations
- 12.1.8 Recent Developments
12.2 Harmony Biosciences Holdings, Inc.
- 12.2.1 Overview
- 12.2.2 Financials
- 12.2.3 Narcolepsy Treatment Portfolio
- 12.2.4 Commercial Strategy
- 12.2.5 Key Products
- 12.2.6 Market Position
- 12.2.7 Strategic Collaborations
- 12.2.8 Recent Developments
12.3 Avadel Pharmaceuticals plc
- 12.3.1 Overview
- 12.3.2 Financials
- 12.3.3 Narcolepsy Treatment Portfolio
- 12.3.4 Commercial Strategy
- 12.3.5 Key Products
- 12.3.6 Market Position
- 12.3.7 Strategic Collaborations
- 12.3.8 Recent Developments
12.4 Takeda Pharmaceutical Company Limited
- 12.4.1 Overview
- 12.4.2 Financials
- 12.4.3 Narcolepsy Treatment Portfolio
- 12.4.4 Commercial Strategy
- 12.4.5 Key Products
- 12.4.6 Market Position
- 12.4.7 Strategic Collaborations
- 12.4.8 Recent Developments
12.5 Axsome Therapeutics, Inc.
- 12.5.1 Overview
- 12.5.2 Financials
- 12.5.3 Narcolepsy Treatment Portfolio
- 12.5.4 Commercial Strategy
- 12.5.5 Key Products
- 12.5.6 Market Position
- 12.5.7 Strategic Collaborations
- 12.5.8 Recent Developments
12.6 Centessa Pharmaceuticals plc
- 12.6.1 Overview
- 12.6.2 Financials
- 12.6.3 Narcolepsy Treatment Portfolio
- 12.6.4 Commercial Strategy
- 12.6.5 Key Products
- 12.6.6 Market Position
- 12.6.7 Strategic Collaborations
- 12.6.8 Recent Developments
12.7 Alkermes plc
- 12.7.1 Overview
- 12.7.2 Financials
- 12.7.3 Narcolepsy Treatment Portfolio
- 12.7.4 Commercial Strategy
- 12.7.5 Key Products
- 12.7.6 Market Position
- 12.7.7 Strategic Collaborations
- 12.7.8 Recent Developments
12.8 NLS Pharmaceutics Ltd.
- 12.8.1 Overview
- 12.8.2 Financials
- 12.8.3 Narcolepsy Treatment Portfolio
- 12.8.4 Commercial Strategy
- 12.8.5 Key Products
- 12.8.6 Market Position
- 12.8.7 Strategic Collaborations
- 12.8.8 Recent Developments
12.9 Aardvark Therapeutics, Inc.
- 12.9.1 Overview
- 12.9.2 Financials
- 12.9.3 Narcolepsy Treatment Portfolio
- 12.9.4 Commercial Strategy
- 12.9.5 Key Products
- 12.9.6 Market Position
- 12.9.7 Strategic Collaborations
- 12.9.8 Recent Developments
12.10 Zevra Therapeutics, Inc.
- 12.10.1 Overview
- 12.10.2 Financials
- 12.10.3 Narcolepsy Treatment Portfolio
- 12.10.4 Commercial Strategy
- 12.10.5 Key Products
- 12.10.6 Market Position
- 12.10.7 Strategic Collaborations
- 12.10.8 Recent Developments

13. Treatment Gap Analysis

13.1 Unmet Clinical Needs
13.2 Treatment Limitations Assessment
13.3 Access and Affordability Challenges
13.4 Innovation Opportunities
13.5 Future Treatment Potential

14. Future Outlook and Strategic Recommendations

14.1 Emerging Treatment Trends
14.2 Orexin-Based Therapy Market Potential
14.3 Innovation Roadmap
14.4 Strategic Opportunities for Stakeholders
14.5 Future Treatment Landscape Outlook

15. Research Methodology

15.1 Primary Research
15.2 Secondary Research
15.3 Treatment Landscape Assessment Framework
15.4 Data Validation and Triangulation
15.5 Assumptions and Limitations

16. Appendix

16.1 Abbreviations
16.2 Glossary of Terms
16.3 References
16.4 List of Tables
16.5 List of Figures
16.6 Regulatory Sources
16.7 Company Sources
16.8 Clinical Guidelines Sources
16.9 Scientific Literature Sources

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

嗜睡症治療市場－全球預測，2026-2032年

嗜睡症治療市場：2026-2032年全球市場預測（依藥物類別、疾病類型、年齡層、劑型及通路分類）

全球發作性睡病流行病學分析與預測（2026 年）

全球嗜睡症市場：競爭分析（2026 年）

全球嗜睡症治療產品線分析（2026 年）（第二季洞察與臨床試驗）

全球發作性睡病臨床試驗現況：趨勢與分析（2026 年版）

嗜睡症治療市場規模、佔有率和成長分析：按藥物類別、通路、嗜睡症類型和地區分類－2026-2033年產業預測

嗜睡症治療市場報告：按類型、疾病、治療方法和地區分類（2026-2034 年）

嗜睡症治療市場－全球產業規模、佔有率、趨勢、機會、預測：依治療方法、產品、地區和競爭格局分類，2021-2031年

發作性睡病治療市場規模、佔有率和成長分析（按治療類型、疾病類型和地區分類）—產業預測（2026-2033 年）

▼

FAQ

全球嗜睡症治療市場：策略性洞察與預測（2026-2035 年）